Compass Psilocybin Depression Trials Succeed
Compass Pathways announced promising results from two Phase 3 trials of its psilocybin-based drug for severe depression. While findings are preliminary and further analysis is needed, early results suggest psychedelic-assisted therapy may become a mainstream option for those who haven't responded to traditional treatments.
- The two Phase 3 trials, known as COMP005 and COMP006, involved over 800 participants with treatment-resistant depression. The larger of the two studies included 581 dosed participants across North America and Europe. - The primary measure of success in the trials was the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at week six. In the COMP006 trial, the group receiving a 25mg dose of COMP360 showed a 3.8-point greater reduction in depression symptoms compared to the 1mg control group. - In one of the Phase 3 trials, 39% of participants who received the 25mg dose achieved a clinically meaningful reduction in their depression symptoms by the sixth week. Data from the other trial indicated that for many responders, the positive effects were maintained for at least 26 weeks. - The treatment, COMP360, is a proprietary, synthetic formulation of psilocybin, the psychoactive compound found in "magic mushrooms". In the trials, it was administered in conjunction with psychological support from trained therapists. - The most common side effects reported were generally mild to moderate and included headache, nausea, anxiety, and visual hallucinations, with most resolving within a day of administration. The rate of serious adverse events like suicidal ideation was less than 1% across both trials. - Following these results, Compass Pathways has requested a meeting with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission for a New Drug Application (NDA). The company expects to complete the NDA submission in the fourth quarter of 2026. - This psilocybin-based therapy has been granted Breakthrough Therapy designation by the FDA, a process designed to expedite the development and review of drugs for serious conditions.
